List of Excipients in Branded Drug QVAR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
STAT RX USA LLC	QVAR	beclomethasone dipropionate	16590-860	ALCOHOL
STAT RX USA LLC	QVAR	beclomethasone dipropionate	16590-860	NORFLURANE
A-S Medication Solutions	QVAR	beclomethasone dipropionate	50090-1342	ALCOHOL

QVAR Excipient Strategy, Patent Position, Generic Risk, and Commercial Opportunities

Last updated: August 30, 2026

QVAR is a beclomethasone dipropionate inhalation aerosol marketed by Teva Pharmaceuticals for maintenance treatment of asthma. Its commercial differentiation rests less on the corticosteroid itself than on the formulation-device system: a hydrofluoroalkane propellant, ethanol cosolvent, metered-dose delivery, breath-actuated operation in QVAR RediHaler, and dose-counting technology. The main opportunity for competitors is to reproduce equivalent lung delivery, device performance, and patient usability while avoiding formulation, manufacturing, and device patents.

What is QVAR and which formulation is commercially marketed?

QVAR contains beclomethasone dipropionate, an inhaled corticosteroid. The current U.S. product is QVAR RediHaler, an HFA-134a pressurized metered-dose inhaler available in 40 mcg and 80 mcg strengths per actuation.[1]

Attribute	QVAR RediHaler
Active ingredient	Beclomethasone dipropionate
Therapeutic class	Inhaled corticosteroid
U.S. indication	Maintenance treatment of asthma
Dosage form	Inhalation aerosol
Strengths	40 mcg and 80 mcg per actuation
Propellant	HFA-134a, also known as 1,1,1,2-tetrafluoroethane
Cosolvent	Ethanol
Device	Breath-actuated metered-dose inhaler
FDA application	NDA 208911 for QVAR RediHaler
Administration	Oral inhalation
Rescue use	Not indicated for acute bronchospasm
Biosimilar pathway	Not applicable; beclomethasone dipropionate is a small molecule

QVAR RediHaler replaced earlier QVAR formulations that required coordination between actuation and inhalation. The RediHaler device is breath actuated and does not require patients to prime, shake, or coordinate actuation with inhalation in the same manner as a conventional press-and-breathe inhaler.[1]

What excipients are used in QVAR RediHaler?

QVAR RediHaler uses a relatively short excipient platform. The FDA prescribing information identifies ethanol and HFA-134a as inactive ingredients.[1]

Excipient composition and technical function

Excipient or component	Function in QVAR
HFA-134a	Propellant and aerosolization medium
Ethanol	Cosolvent that supports drug solubilization and spray characteristics
Aluminum canister	Primary product container
Metering valve	Delivers a controlled volume per actuation
Breath-actuated mechanism	Triggers aerosol release during inhalation
Dose counter	Communicates remaining labeled doses

The formulation is commercially important because beclomethasone dipropionate must be delivered consistently to the lungs in a low-dose aerosol. The formulation must control:

• Drug solubility or dispersion behavior.
• Valve metering.
• Plume geometry.
• Aerodynamic particle-size distribution.
• Delivered-dose uniformity.
• Priming and repriming behavior.
• Stability during storage.
• Compatibility between formulation, canister, valve, actuator, and breath-actuation mechanism.

The short excipient list does not make development simple. Pressurized inhaler performance depends on the interaction of the formulation and device. A change in ethanol concentration, valve materials, canister coating, or actuator geometry can change emitted dose and fine-particle dose.

Why does QVAR use HFA-134a and ethanol?

HFA-134a replaced chlorofluorocarbon propellants used in earlier inhalers because of environmental restrictions on ozone-depleting substances. HFA-134a has been widely used in pressurized metered-dose inhalers and has an established pharmaceutical supply chain.[2]

Ethanol acts as a cosolvent. It can improve dissolution of beclomethasone dipropionate and influence spray plume characteristics. Ethanol concentration also affects vapor pressure, evaporation rate, valve behavior, and the amount of drug reaching the respirable particle-size range.

The formulation strategy creates several development constraints:

1. The drug must remain chemically and physically stable during the product shelf life.
2. The valve must deliver a reproducible metered volume.
3. The formulation must generate a clinically comparable aerosol.
4. The device must retain performance over the labeled number of actuations.
5. The product must tolerate temperature and orientation variations encountered during distribution and use.

A competitor cannot assume that substituting another HFA propellant or changing ethanol levels will preserve equivalence. Any material change can require new in vitro studies and, depending on the effect, additional pharmacokinetic or clinical support.

What formulation patents protect QVAR?

QVAR protection is likely distributed across several patent categories rather than confined to the active ingredient:

• Beclomethasone dipropionate inhalation formulations.
• HFA-based aerosol compositions.
• Ethanol-containing solutions or suspensions.
• Valve and metering systems.
• Breath-actuated inhaler mechanisms.
• Actuator and dose-counter architecture.
• Manufacturing and filling processes.
• Use of the formulation for asthma maintenance.

The original beclomethasone dipropionate molecule is an old corticosteroid and is not the primary exclusivity barrier. Commercial protection has instead depended on the inhalation product, device configuration, formulation process, and regulatory exclusivity.

Patent status must be assessed through the current FDA Orange Book listing for the applicable NDA and through the USPTO and litigation records. Patent numbers and expiration dates should not be inferred from the active ingredient or from older QVAR products because the RediHaler device and formulation are separate products with separate regulatory histories.[3]

Are method-of-use patents important for QVAR?

Method-of-use patents can cover maintenance treatment of asthma, dosing regimens, patient populations, or administration conditions. Their commercial value is generally lower than a formulation or device patent if a generic applicant can use a section viii statement to omit the patented indication from its labeling.

A method-of-use patent becomes more commercially relevant when:

• The patented use is central to the product label.
• The label cannot be practically carved out.
• The patent covers the dominant prescribing population.
• The patent is listed in the Orange Book and can support a Paragraph IV dispute.

What is the FDA regulatory status of QVAR?

QVAR RediHaler is an FDA-approved prescription inhalation aerosol. It is regulated as a drug-device combination product because the drug formulation and inhaler device jointly determine product performance.[1]

For an abbreviated new drug application, a generic sponsor generally must establish pharmaceutical equivalence and bioequivalence, including comparable performance of the inhalation product. FDA guidance for orally inhaled products emphasizes that in vitro characterization is central to demonstrating equivalence. Relevant studies may include:

• Single-actuation content.
• Delivered-dose uniformity.
• Aerodynamic particle-size distribution.
• Spray pattern and plume geometry.
• Priming and repriming.
• Microbiological quality where relevant.
• Device robustness.
• Leachables and extractables.
• Stability.
• Comparative product performance.

FDA’s product-specific guidance for beclomethasone dipropionate inhalation aerosol should be reviewed for the current recommended ANDA evidence package.[4]

How strong is QVAR’s excipient and device patent estate?

QVAR’s formulation protection is stronger than an active-ingredient patent analysis would suggest, but the overall estate depends on the surviving scope and expiration of device and formulation claims.

Protection layer	Strategic value	Generic vulnerability
Beclomethasone dipropionate API	Low	Old molecule and established synthesis
HFA-134a/ethanol formulation	Medium to high	Design-around may be possible, but equivalence must be proven
Metered-dose valve	Medium	Alternative valve systems may be available
Breath-actuated mechanism	High	Device redesign can increase cost and regulatory risk
Dose counter and actuator	Medium	Potentially avoidable through a different architecture
Manufacturing process	Medium	Process claims may be difficult to detect or enforce
Method of use	Variable	Label carve-out may reduce exposure
Regulatory exclusivity	Time-limited	Depends on NDA and supplement history

The strongest practical barrier may be device replication and equivalence rather than the excipient identity. A generic sponsor must produce an inhaler that performs consistently in actual patient use. Device usability, actuation force, inspiratory-flow requirements, and dose delivery can determine substitution risk even when the chemical formulation appears simple.

When does QVAR lose exclusivity?

QVAR has passed its original new-drug exclusivity period. The commercial question is now patent expiry, Orange Book listing status, and the availability of an approvable generic product.

The relevant exclusivity timeline is:

Milestone	Commercial significance
Original QVAR approval	Established the initial beclomethasone HFA product
QVAR RediHaler approval	Added the breath-actuated product platform
Five-year NCE exclusivity	Not the principal current barrier
Three-year supplement exclusivity	May apply to qualifying new clinical investigations
Listed patents	Can delay or complicate ANDA approval
Paragraph IV litigation	May create a 30-month FDA approval stay
Patent expiry or successful challenge	Opens potential generic entry
First ANDA approval	Can change payer and formulary economics

The exact commercial entry date cannot be determined from the active ingredient alone. It depends on the current Orange Book patent listings, the filing date and certification of each ANDA, any Paragraph IV litigation, settlement terms, pediatric exclusivity, and court decisions.[3,5]

Which companies are challenging QVAR?

Publicly identifiable QVAR challengers should be determined from current FDA ANDA records, Orange Book patent certifications, and federal litigation databases. A company may challenge the product without immediate market entry, and an ANDA applicant may remain confidential before approval or litigation.

The main potential competitor groups are:

• Large generic inhaler companies with metered-dose manufacturing capacity.
• Contract development and manufacturing organizations with aerosol-filling infrastructure.
• Specialty respiratory companies with proprietary inhaler devices.
• Companies pursuing authorized-generic or supply agreements.
• Firms with existing beclomethasone or inhaled corticosteroid portfolios.

A challenge based only on a different excipient composition may face a higher equivalence burden. A challenge using the same HFA-134a and ethanol platform could reduce formulation risk but increase exposure to composition-of-matter, manufacturing, or device claims.

What generic launch risks exist for QVAR?

Three launch scenarios are commercially realistic.

1. At-risk launch

The generic launches before all asserted patents expire after the sponsor wins litigation or accepts potential damages exposure. This strategy can accelerate share capture but creates substantial injunction and damages risk.

2. Authorized or licensed entry

Teva or another rights holder licenses a competing product or supplies an authorized generic. This reduces litigation exposure but can preserve brand control over pricing and channel strategy.

3. Post-expiry entry

The generic launches after listed patents expire or after a settlement date. This is the lowest legal-risk path but may face entrenched formulary contracts and limited remaining branded pricing power.

Market substitution may be slower than for oral tablets because physicians and payers evaluate inhaler technique, device familiarity, training, and formulary positioning. A generic that requires different inhalation behavior may not achieve automatic substitution even if FDA-rated therapeutically equivalent.

What commercial opportunities exist in QVAR excipients?

HFA-to-lower-global-warming-potential reformulation

HFA-134a has a high global-warming potential. Pharmaceutical companies are evaluating lower-global-warming-potential propellants, including HFA-152a and hydrofluoroolefin-based systems. Reformulation can create a lifecycle-management opportunity if the new product maintains dose delivery and clinical performance while improving environmental metrics.[6]

The key technical risks are:

• Different vapor pressure.
• Different density and solvency.
• Changed plume force.
• Valve compatibility.
• Canister and elastomer compatibility.
• Altered particle-size distribution.
• New stability profile.
• Need for new device and human-factors work.

Excipient and component supply

Commercial opportunities exist in:

• Pharmaceutical-grade ethanol supply.
• Low-global-warming-potential propellant supply.
• Coated aluminum canisters.
• Low-extractables valve elastomers.
• Metering valves.
• Breath-actuated mechanisms.
• Dose counters.
• Aerosol-filling and assembly services.
• Analytical testing for aerodynamic performance.

Supply security is strategically important because inhaler manufacturing requires specialized filling lines and validated component combinations. A supplier that qualifies an alternative valve, canister, or propellant can gain switching costs and long-term contract value.

Device-focused differentiation

A lower-cost generic device could compete through:

• Easier actuation.
• Improved dose-counter visibility.
• Reduced residual drug.
• Better performance at lower inspiratory flow.
• More robust priming and repriming.
• Recyclable or lower-material packaging.
• Integration with adherence monitoring.

These changes must preserve substitutability and may require additional human-factors and performance evidence.

How does QVAR compare with competing inhaled corticosteroids?

Product class	Active ingredient	Device/formulation distinction	Competitive implication
QVAR RediHaler	Beclomethasone dipropionate	Breath-actuated HFA aerosol	Device-led differentiation
Flovent HFA	Fluticasone propionate	HFA metered-dose inhaler	Established corticosteroid comparator
Pulmicort Flexhaler	Budesonide	Dry-powder inhaler	Different device and lung-delivery platform
Alvesco	Ciclesonide	HFA metered-dose inhaler	Prodrug and formulation differentiation
Arnuity Ellipta	Fluticasone furoate	Dry-powder inhaler	Once-daily device-led product
Generic inhaled corticosteroids	Various	Device-specific	Price competition constrained by device usability

QVAR’s positioning is strongest where breath actuation improves usability for patients who struggle with hand-breath coordination. Its weakness is exposure to generic inhaled corticosteroid substitution and payer preference for lower-cost alternatives.

What revenue exposure does QVAR create for Teva?

Teva does not generally report QVAR revenue as a separately disclosed material line item in its principal public financial reporting. Revenue exposure is therefore best evaluated through product status, prescription volume, gross-to-net pricing, formulary position, and generic competition rather than a company-reported QVAR sales figure.[7]

The main commercial risks are:

• Generic price erosion.
• Loss of preferred formulary placement.
• Substitution by dry-powder inhalers.
• Reduced use of branded inhaled corticosteroids.
• Lower reimbursement for device-based products.
• Litigation or settlement costs.
• Supply interruptions involving propellant or valve components.

Lifecycle-management value could come from an environmentally improved propellant, a lower-cost authorized generic, a pediatric or adherence-oriented device, or a coformulated product that competes in broader asthma treatment categories.

Key Takeaways

• QVAR’s core excipients are HFA-134a and ethanol.
• The main strategic asset is the formulation-device system, not the old beclomethasone molecule.
• Breath actuation, dose metering, aerosol performance, and device usability are central generic barriers.
• QVAR is a small-molecule product and has no biosimilar pathway.
• Current patent and launch analysis requires the live Orange Book, USPTO records, and litigation filings.
• Lower-global-warming-potential propellants are the clearest long-term excipient and lifecycle-management opportunity.
• Generic competition is technically feasible but requires specialized inhaler development, filling, and equivalence testing.
• Public financial reporting does not generally isolate QVAR revenue, limiting direct revenue-exposure quantification.

FAQs

Can ethanol be removed from a QVAR generic formulation?

Yes, a sponsor may pursue a different formulation, but removing ethanol can affect drug solubility, valve performance, plume geometry, delivered dose, and aerodynamic particle-size distribution. The alternative must meet FDA equivalence requirements.

Is QVAR a suspension or solution inhaler?

QVAR RediHaler is described in FDA labeling as an inhalation aerosol using HFA-134a and ethanol. Product classification should be confirmed against the current FDA label and chemistry, manufacturing, and controls documentation because formulation terminology affects the equivalence strategy.

Can a generic use the QVAR RediHaler device?

A generic sponsor may use a similar or different device, subject to FDA requirements. Copying the device can reduce user-interface differences but may increase patent and trade-dress exposure.

Are HFA-152a propellants suitable for QVAR replacement?

HFA-152a is a potential lower-global-warming-potential propellant, but suitability depends on drug solubility, pressure, flammability controls, valve compatibility, aerosol performance, stability, and FDA acceptance of the complete product.

Does QVAR have biologic or biosimilar competition?

No. Beclomethasone dipropionate is a chemically synthesized small molecule. Competition proceeds through the ANDA pathway or a full NDA, not through the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2023). QVAR RediHaler (beclomethasone dipropionate) inhalation aerosol prescribing information. Teva Pharmaceuticals USA, Inc.

2. U.S. Environmental Protection Agency. (n.d.). Protection of stratospheric ozone: Substitutes in the refrigeration and air conditioning, fire suppression, and solvent sectors. https://www.epa.gov/ozone-layer-protection

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2020). Product-specific guidance for beclomethasone dipropionate inhalation aerosol. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (n.d.). Hatch-Waxman exclusivity and patent certification procedures. https://www.fda.gov

6. International Pharmaceutical Aerosol Consortium on Regulation and Science. (2023). Transitioning to low-global-warming-potential propellants in metered-dose inhalers. IPAC-RS.

7. Teva Pharmaceutical Industries Ltd. (2024). Annual report on Form 20-F. U.S. Securities and Exchange Commission.